AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02542384
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Trial: NCT00484718
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral bid
Trial: NCT04317833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT01350154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate oral in gelatine capsules, 3 times daily
Trial: NCT02999399
Drug: Deuterated Phenanthrene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
Trial: NCT00415532
Drug: Medical Standard of Care for ITP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00311662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet once daily for 12 weeks
Trial: NCT03652961
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
Trial: NCT00062556
Drug: Niacin Extended Release and Lovastatin Tablets
RxNorm normalized name: lovastatin / niacin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02125578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive placebo every other week or every 4 weeks.
Trial: NCT02583373
Drug: CAL02 High-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
Trial: NCT02583373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered administered 2 times (24 hours apart) as i.v. infusion
Trial: NCT04629885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo gel with identical appearance to the test product, used as reference treatment.
Trial: NCT03165734
Drug: Physician's Choice medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
Trial: NCT04233034
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill manufactured to mimic verapamil 120mg tablet
Trial: NCT00401856
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg oral route
Trial: NCT00401856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is identical to eplerenone but the active ingredient is absent
Trial: NCT00674973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
Trial: NCT01951183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO681135 placebo subcutaneously daily
Trial: NCT01951183
Drug: RO6811135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously daily
Trial: NCT00654303
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02496962
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo were taken daily for 5 days
Trial: NCT03034200
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 625mg ONC201 will be given on two consecutive days each week
Trial: NCT01050127
Drug: ABT-436
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm Description for details.
Trial: NCT01050127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm Description for details.
Trial: NCT04012918
Drug: Capecitabine plus aromatase inhibitor
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
Trial: NCT00695578
Drug: Biafine
RxNorm normalized name: Biafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
Trial: NCT00752024
Drug: dehydrating agent, haemostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Trial: NCT00054717
Drug: Comparator Protease Inhibitor (CPI)
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04622735
Drug: Paracetamol 500 Mg Oral Tablet X2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
Trial: NCT04318652
Drug: Methylprednisolone eyedrops
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: instillation of methylprednisolone eye drops
Trial: NCT01149616
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline IV x1
Trial: NCT05608590
Drug: Lipiodol UltraFluid
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
Trial: NCT05945745
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: different treatments based on the molecular analysis
Trial: NCT01706692
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: all dosages, frequencies and durations prescribed
Trial: NCT04328805
Drug: ibuprofen tablets
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT03304821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
Trial: NCT02278341
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
Trial: NCT00146289
Drug: MICARDIS® (telmisartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01773278
Drug: Antioxidants
RxNorm normalized name: E Complex with Antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
Trial: NCT01773278
Drug: Cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible
Trial: NCT00162786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00427960
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 5 mg
Trial: NCT01956084
Drug: LMP1/2 CTLs (Group A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2
Trial: NCT01956084
Drug: LMP1/2 CTLs (Group B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2
Trial: NCT01200394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, placebo once daily for 12 weeks
Trial: NCT02962947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily
Trial: NCT01508156
Drug: IDX719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX719 liquid suspension (1 - 100 mg) taken by mouth.
Trial: NCT01508156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liquid suspension matching IDX719 taken by mouth.
Trial: NCT02525029
Drug: Pregnyl®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I.
Trial: NCT02678897
Drug: Oxynorm via PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5.
Trial: NCT01337154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, orally, daily
Trial: NCT01263899
Drug: SB1518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
Trial: NCT01678027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
Trial: NCT01678027
Drug: LAC triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
Trial: NCT00728052
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
Trial: NCT00728052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be administered orally with water.
Trial: NCT02902978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6130 matched placebo
Trial: NCT00287079
Drug: Rebif®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
Trial: NCT04083339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
Trial: NCT01539642
Drug: Sufentanil NanoTab PCA System/15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
Trial: NCT01539642
Drug: Placebo Sufentanil NanoTab PCA System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
Trial: NCT02751632
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
Trial: NCT02751632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
Trial: NCT02281630
Drug: KWA-0711
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03051646
Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
Trial: NCT03051646
Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Trial: NCT03311009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo provided as oral tablets q.d.
Trial: NCT01743677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose placebo tablets (5 tablets)
Trial: NCT02753218
Drug: LEO 32731
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03190369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Intra articular
Trial: NCT00905216
Drug: heparin sodium - Bergamo
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.000 UI/mL
Trial: NCT00905216
Drug: heparin sodium - APP
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.000 USP
Trial: NCT02963831
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
Trial: NCT00409578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
Trial: NCT02783885
Drug: immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02476422
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of diclofenac 50 mg soft gelatin capsule
Trial: NCT02476422
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of ibuprofen 400 mg tablet
Trial: NCT02476422
Drug: Placebo to ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo to ibuprofen 400 mg tablet
Trial: NCT02476422
Drug: Placebo to diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
Trial: NCT00138177
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00138177
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03120442
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.25 mcg fo Fentanyl for anxiolysis
Trial: NCT02301611
Drug: TLPLDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor lysate, particle-loaded dendritic cell vaccine
Trial: NCT02301611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00190554
Drug: Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03036306
Drug: SCX-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam cream formulation
Trial: NCT00190554
Drug: (Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02947932
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: post-ERCP intervention in high risk patients
Trial: NCT02291744
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
Trial: NCT04147572
Drug: Placebo Spiriva capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation from HandiHaler
Trial: NCT03715153
Drug: BUMETANIDE (S95008) for week 0 - 26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution dosed at 0.5 mg/mL Taken twice daily.
Trial: NCT03715153
Drug: PLACEBO for week 0 - 26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution Taken twice daily.
Trial: NCT03715153
Drug: Open-Label BUMETANIDE (S95008) for weeks 26 - 52
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution dosed at 0.5 mg/mL Taken twice daily.
Trial: NCT01699854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03057509
Drug: Ga-68-DOTA-TOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
Trial: NCT02876835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Trial: NCT00076973
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 6 months